Become a member to receive our newsletter and get unrestricted access to downloadable slidekits...
A confirmation email has been sent to
Please click on the Activation Link to activate your account. If you don't receive our email, please check your spam folder.
Confirm your password
I agree to receive
the R3i newsletter
Forgot your codes?
Download this slidekit...
Differentiating SPPARMα and fibrates (PPARα agonists)
Professor Jean-Charles Fruchart PharmD, PhD President of the R3i Foundation.
Atherosclerotic cardiovascular disease (ASCVD) is a growing global health challenge, exacerbated by a changing risk factor landscape associated with chronic lifestyle-related diseases such as visceral obesity, type 2 diabetes mellitus (T2DM), and non-alcoholic fatty liver disease. Atherogenic dyslipidemia, elevated triglycerides with or without low levels of high-density lipoprotein cholesterol, is common to high-risk individuals, especially those with T2DM, and contributes to residual cardiovascular risk despite optimal low-density lipoprotein cholesterol control.
Current options for managing atherogenic dyslipidemia issues, especially for renal and hepatic safety. New approaches are clearly needed.
The SPPARMα concept provides a precision medicine approach
to this problem This booklet discusses the evidence for the novel
SPPARMα agonist, pemafibrate, that differentiates it as a distinct
therapeutic class from traditional fibrates.
The ultimate test for SPPARMα is the PROMINENT cardiovascular outcomes trial, which is evaluating whether treatment with pemafibrate safely reduces residual cardiovascular risk in high-risk T2DM patients
with atherogenic dyslipidemia.
SSPARMα at the Crossroads of Obesity, Diabetes and Cardiovascular Diseases - SECOND EDITION
Originally created by Professor Jean-Charles Fruchart, President of the R3i Foundation and an internationally recognised leader in the field of PPARα research, this free-to-down slide library has been updated. The slides now include the latest information on the role of triglyceride-rich lipoproteins and their remnants in residual vascular risk, as well as the REDUCE-IT and STRENGTH cardiovascular outcomes studies.
The slide library comprises 276 slides covering:
• Atherosclerosis, metabolic syndrome, Type 2 diabetes (T2D) and associated macro- and microvascular diseases, specifically focussing on the effects of dyslipidaemia and inflammation.
• Background to triglyceride-rich lipoproteins and their remnants in residual vascular risk
• What’s new in clinical outcomes studies of triglyceride-lowering therapies.
A key focus of the slide library is the concept of selective PPARα modulation (SPPARMα), which aims to improve efficacy and minimise safety issues such as elevation in serum creatinine evident with current PPARα agonists (fibrates). The novel SPPARMα agonist pemafibrate is currently being evaluated in the PROMINENT cardiovascular outcomes study. This landmark trial will test whether treatment with this SPPARMα agonist, against a background of best evidence-based therapy including statins, reduces cardiovascular events in high risk patients with atherogenic dyslipidemia, the combination of elevated triglycerides and low HDL-C. This is the final critical test of the SPPARMα concept.
Created by Professors Jean Davignon (Vice-President of the R3i foundation), Jean-Charles Fruchart (President of R3i) and Michel Hermans (R3i General Secretary), the latest downloadable deck of 242 slides discusses the potential role for anti-PCSK9 mAbs in the future management of cardiovascular disease.
Authors review unmet needs in the treatment of dyslipidemia, the discovery and structure of PCSK9,PCSK9 levels in health and disease, PCSK9-drug interactions focusing on statin trials, current approaches to PCSK9 inhibition, and recent results from anti-PCSK9 mAb pre-clinical and clinical trials.